Share on StockTwits

Masimo (NASDAQ:MASI) has earned an average rating of “Hold” from the seven ratings firms that are covering the stock, Analyst Ratings.Net reports. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $26.67.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Masimo in a research note on Monday, August 11th. They now have a $23.00 price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Masimo in a research note on Monday, August 11th. They now have a $27.00 price target on the stock, down previously from $29.00. Finally, analysts at BMO Capital Markets cut their price target on shares of Masimo from $26.00 to $24.00 in a research note on Friday, August 8th.

Shares of Masimo (NASDAQ:MASI) opened at 21.92 on Monday. Masimo has a 1-year low of $19.30 and a 1-year high of $32.20. The stock’s 50-day moving average is $23.82 and its 200-day moving average is $25.46. The company has a market cap of $1.200 billion and a price-to-earnings ratio of 20.49.

Masimo (NASDAQ:MASI) last released its earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.29 by $0.05. The company had revenue of $140.92 million for the quarter, compared to the consensus estimate of $145.76 million. During the same quarter in the prior year, the company posted $0.30 earnings per share. The company’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts expect that Masimo will post $1.25 EPS for the current fiscal year.

Masimo Corporation, is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring products.

Receive News & Ratings for Masimo Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co and related companies with Analyst Ratings Network's FREE daily email newsletter.